Recently, Shengshi Tyco's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has obtained the implied license for clinical trials from the State Drug Administration.CGT-2201, which targets SGLT-2 and DPP-4, two important targets of glucose metabolism, can be better used in the treatment of diabetes and its derived diseases, including diabetic nephropathy and non-alcoholic fatty liver disease.
In 2021, the number of diabetes patients in China has reached 141 million, ranking first in the world. Among many diabetic patients in China, 20~40% may suffer from diabetic nephropathy complications. Among the existing hypoglycemic drugs, only sodium-glucose cotransporter 2 (SGLT-2) inhibitors have a significant renal protective effect in clinical verification, but the inherent risk of reproductive and urinary system infection limits its application. Based on the SGLT-2 inhibitor, combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitor, the design and development of a drug that can improve blood glucose, reduce the side effects of urinary and reproductive system infections, without kidney function restrictions, and has kidney benefits, is expected to fill the market gap and meet the needs of patients.
Based on this market background and target characteristics, Shengshiteko uses its own small-molecule chimera drug technology platform to develop multi-functional new drug products with synergistic mechanism, and CGT-2201 is one of its representative works. It combines the respective mechanism characteristics of SGLT-2 and DPP-4, on the basis of inhibiting SGLT-2 activity to reduce the reabsorption of glucose in the kidney, slowing the inactivation of DPP-4 on GLP-1, and reducing the side effects of urinary infection of existing SGLT-2 drugs; at the same time, reducing renal burden and reducing the use of contraindications in diabetic patients without renal insufficiency. Therefore, the drug will have the advantage of better blood glucose control and protecting the kidney function of the patients.
Shengshitaike was founded in Suzhou Industrial Park in 2010. The core team has decades of working experience in the whole life cycle of international drugs, and is committed to the research and development and industrialization of small-molecule innovative drugs with high-quality and differentiated drugs. With the integrated drug research and development technology platform and diversified business vision, the company has built a product pipeline covering a number of diseases such as hypoglycemic, anti-cancer and autoimmunity. In the field of hypoglycemic drugs, shengagliptin, the core product independently developed by the company, has submitted NDA (product marketing application) to the State Food and Drug Administration and was accepted. The results of phase 3 clinical trial show that the low dose can reach the preset trial end point, and the high dose group can also show the safety of the drug. The "amount" and half the effect makes it expected to become the best hypoglycemic drug in its class. At the same time, the company has also made a comprehensive layout of oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical practice, is one of the members of its pipeline matrix.
